HDAC1 activator-1
HDAC1 activator-1 is a specific HDAC1 activator with orally activity, exerting no significant effects on other HDAC family members. HDAC1 activator-1 exhibits neuroprotective activity, ameliorates cognitive and motor function deficits by reducing neuronal loss and gliosis. HDAC1 activator-1 specifically activates HDAC1 in SH-SY5Y cells and exerts regulatory effects on aberrant cell cycle and DNA damage. HDAC1 activator-1 can be used for the research of TDP-43 proteinopat1-related neurodegenerative diseases including Amyotrophic Lateral Sclerosis (ALS) and cerebral ischemia-related neurological injury.
For research use only. We do not sell to patients.
- CAS No.: 300399-36-4
- Formula: C17H24O4
- Molecular Weight:292.37
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
|
HDAC1 |
In Vitro
HDAC1 Activator-1 (cpd 5104434) (1 μM-50 μM) shows dose-dependent activation of HDAC1 enzymatic activity, with no significant effects on HDAC2, HDAC3, and HDAC8, exhibiting high selectivity for HDAC1[1][2].
HDAC1 Activator-1 (1 μM-50 μM; 72 h) specifically activates HDAC1 in the human neuroblastoma cell line SH-SY5Y in vitro[1][2].
HDAC1 Activator-1 (2.5 μM, 25 μM) restores HDAC1 enzymatic activity in primary cortical neurons subjected to oxygen-glucose deprivation (OGD)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Human neuroblastoma SH-SY5Y cell line
-
Concentration:1 μM, 10 μM, 50 μM
-
Incubation Time:72 h
-
Result:Enhances HDAC1 deacetylation function without altering its protein expression.
In Vivo
HDAC1 Activator-1 (6 mg/kg; i.p.; 5 days a week; for 2 months) ameliorates cognitive deficits (Morris water maze, novel object recognition test) and motor dysfunction (rotarod test), reverses aberrant cell cycle, DNA damage, neuronal loss and gliosis in FTLD-TDP transgenic mice[1][2].
HDAC1 Activator-1 (6 mg/kg; i.p.; 5 days a week; for 2 months) ameliorates cognitive deficits (Morris water maze, novel object recognition test) and motor dysfunction (rotarod test), reverses aberrant cell cycle, DNA damage, neuronal loss and gliosis in FTLD-TDP transgenic mice[1][2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female and male FTLD-TDP transgenic (Tg) mice (6 months old) and age-matched wild-type (WT) FVB mice[1].
-
Dosage:6 mg/kg, 30 mg/kg, 0.3 mg/kg
-
Administration:Intraperitoneal (IP); 5 days a week; for 1-2 months
-
Result:Demonstrated significant improvement in cognitive function and motor function.
Restored nuclear HDAC1 activity and reduced acetyl-histone H3 (Lys9/14) levels.
Reversed aberrant cell cycle activity (downregulated E2F1, PCNA, p21) and attenuated DNA damage.
Alleviated neuronal loss and inhibited gliosis.
No significant toxicity (no impact on cell viability, hepatotoxicity, renotoxicity, or body weight).
Chemical Information
-
CAS No. 300399-36-4
-
Molecular Weight 292.37
-
Formula C17H24O4
-
SMILES
O=C1C(CC2C(CC(C)(CC2=O)C)=O)=C(CC(C)(C1)C)O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Genotoxicity/Mutagenicity Study
The bacterial reverse mutation assay detects point mutations that restore amino-acid prototrophy in auxotrophic Salmonella typhimurium or Escherichia coli tester strains; after exposure to a test article, mutagenic activity is read out as an increased number of revertant colonies on minimal agar compared with the vehicle control. The assay uses tester strains with different mutation targets so that base-substitution and frameshift mutagens can be detected, and testing is performed with and without exogenous mammalian metabolic activation because some chemicals require biotransformation to become mutagenic.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- HDAC1 activator-1
- 300399-36-4
- HDAC
- HDAC1 activator
- neuroprotective activity
- inhibits aberrant cell cycle
- DNA damage
- reduces neuronal loss and gliosis
- ameliorates cognitive and motor function deficits
- TDP-43 proteinopathies
- amyotrophic lateral sclerosis (ALS)
- cerebral ischemia
- neurodegenerative diseases
- SH-SY5Y cell line
- HEK-293T cell line
- primary cortical neurons
- frontotemporal lobar degeneration with ubiquitin-positive inclusions (FTLD-TDP) transgenic mice
- rat model of cerebral ischemia
- mouse model of neurodegeneration
- Inhibitor
- inhibitor
- inhibit